Good news! Huibang Biotechnology won the "Star of Creation" Cup Innovative Product Gold Award

Date：

2023-06-01

Good news: Huibang Bio IGFBP-1/fFN won the

"Star of Creation" Cup 2022 Gold Award for Innovative Products

Wisdom medicine is upright and innovative | "Star of Creation" The 8th China Experimental Medicine Conference was grandly opened on May 27 at the Primus Hotel Conference Center in Nanchang! Huibang Bio's innovative product insulin-like growth factor binding protein-1/fetal fiber Connexin (IGFBP-1/fFN) detection kit won the 2022 "Innovation Star" Cup China Excellent Innovative Product Gold Award for In Vitro Diagnostics.

Insulin-like growth factor binding protein-1, referred to as IGFBP-1, is used for the diagnosis of premature rupture of membranes. It has high sensitivity and can detect a small amount of amniotic fluid that cannot be detected by conventional methods. The problem.

Fetal fibronectin, referred to as fFN, is used to predict the risk of premature birth. Between 22 and 35 weeks of pregnancy, the level of fFN in cervicovaginal secretions has a great correlation with whether premature birth occurs. The significance of the fFN test lies in its extremely high negative predictive value. If the result of the fFN test is negative, preterm birth will hardly occur within two weeks (probability <1%).

Huibang Bio's IGFBP-1/fFN detection kit has the following advantages:

1. Joint quantitative detection is an international initiative;

2. Two indicators can be tested at the same time in one sample, which is convenient for doctors to operate, improves patient compliance, and does not require a vaginal speculum, reducing patient pain and sampling risks;

3. Dual detection can determine whether it is a simple risk of premature birth or premature birth combined with premature rupture of membranes;

4. Dynamic quantitative monitoring, prompting the increase and decrease of the risk of premature birth, and giving clinical reference guidance in real time.

5. The reagents are stored at room temperature, which is convenient for storage management, and the reagents are packaged in single servings to avoid waste.

Related News

2024-01-22

Serving the big health industry, leapfrogging development of industry, academia and research - Anhui Huibang Biotech bloomed at the Anhui Traditional Chinese Medicine Academic Annual Conference

2023-08-07

Urine and nephropathy and defense -Dialogue column of the Diabetes Branch of the Chinese Medical Association

On August 4, 2023, the Chinese Medical Association Diabetes Branch 2023 Education Management Academic Conference was grandly held at Fengda International Hotel, Hefei City, Anhui Province.

2023-06-29

Good news! Huibang Biotechnology won the second prize of Science and Technology Progress Award of the Ministry of Education!

Recently, the Ministry of Education issued a certificate for the Outstanding Achievement Award (Science and Technology) of Scientific Research in Institutions of Higher Learning. Anhui Huibang Bioengineering Co., Ltd. jointly with the Chinese Academy of Sciences and Capital Medical University declared the project: "Research and Application of Molecular Targets for Diabetes" won the second prize of Science and Technology Progress Award of the Ministry of Education.

2023-06-12

Huibang Biotech actively implements the Hangzhou Declaration and contributes to building a healthy China

On June 11, 2023, the first China Health Promotion Conference was successfully held in Hangzhou. The conference was high-level and large-scale, and many guests from the government, medical and health circles, sports circles, education circles, science and technology circles, mass media, NGO organizations and business circles attended.

2023-06-01